Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) Issues Earnings Results

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) issued its quarterly earnings data on Friday. The company reported ($2.75) earnings per share for the quarter, FiscalAI reports.

Lakewood-Amedex Biotherapeutics Stock Performance

NASDAQ LABT opened at $2.27 on Friday. The firm has a 50-day moving average of $3.37. The company has a market cap of $5.38 million and a price-to-earnings ratio of -1.14. Lakewood-Amedex Biotherapeutics has a 1-year low of $1.66 and a 1-year high of $98.20.

Analyst Ratings Changes

LABT has been the topic of a number of research reports. Wall Street Zen lowered Lakewood-Amedex Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Weiss Ratings assumed coverage on shares of Lakewood-Amedex Biotherapeutics in a research note on Monday, July 20th. They issued a “sell (e-)” rating for the company. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

About Lakewood-Amedex Biotherapeutics

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.